Cardiovascular Systems Competitors and Similar CompaniesClear all
Cardiovascular Systems's competitors and similar companies include Flow MedTech and LeMaitre Vascular.
 Cardiovascular Systems Cardiovascular Systems, Inc. (CSI) is a medical technology company that develops solutions for the revascularization of patients with complex coronary and peripheral artery disease (PAD). |  LeMaitre Vascular LeMaitre Vascular is a provider of medical devices and human tissue cryopreservation services used in the treatment of peripheral vascular, end-stage renal, and cardiovascular disease. | ||
Founding Date | Founding Date 1989 | Founding Date 2014 | Founding Date 1983 |
Type | Type Public | Type Private | Type Public |
Tags | |||
Locations | Locations Saint Paul, US HQ | Locations Cleveland, US HQ | Locations Burlington, US HQ Kensington, AU Vaughan, CA Shanghai, CN Paris, FR Saint étienne, FR Sulzbach (Taunus), DE see more |
Employees | Employees 7257% decrease | Employees 2 | Employees 59131% increase |
Valuation ($) | Valuation ($) 844 m | Valuation ($) N/A | Valuation ($) 2 b |
Financial | |||
Revenue (est.) | Revenue (est.) $236.2m (FY, 2022) | Revenue (est.) N/A | Revenue (est.) $249.6m (FY, 2025) |
Cost of goods | Cost of goods $63.4m (FY, 2022) | Cost of goods N/A | Cost of goods $71.1m (FY, 2025) |
Gross profit | Gross profit $172.8m (FY, 2022) | Gross profit N/A | Gross profit $178.5m (FY, 2025) |
Net income | Net income ($36.9m) (FY, 2022) | Net income N/A | Net income $57.7m (FY, 2025) |
Funding | |||
Total funding raised | Total funding raised $ 69m | Total funding raised N/A | Total funding raised $ 5.8m |
For sources of this data, please see the company profile
View Company Profiles
Flow MedTech
HQ
Cleveland, US
Employees
2
Flow MedTech is a provider of solutions for cardiovascular problems.
View companyLeMaitre Vascular
HQ
Burlington, US
Employees
591↑ 31% increase
LeMaitre Vascular is a provider of medical devices and human tissue cryopreservation services used in the treatment of peripheral vascular, end-stage renal, and cardiovascular disease.
View company